| Literature DB >> 23411380 |
Waleed F Khalaf1, Meghan E Caldwell, Nishitha Reddy.
Abstract
Enteropathy-associated T-cell lymphoma (EATL) is a rare aggressive lymphoma that confers a poor prognosis with current treatment strategies. Given the rarity of this disease, prospective randomized trials are limited, and thus a standard validated treatment strategy is lacking. This report presents the disease course of a patient with EATL who was treated with single-agent brentuximab vedotin, an anti-CD30 conjugated antibody.Entities:
Mesh：
Substances：
Year: 2013 PMID： 23411380 DOI： 10.6004/jnccn.2013.0021
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908